Endocrinology, Vol 135, 1464-1469, Copyright © 1994 by Endocrine Society

ARTICLES

Down-regulation of type II L-thyroxine, 5'-monodeiodinase in cultured GC cells: different pathways of regulation by L-triiodothyronine and 3,3',5'-triiodo-L-thyronine

Y Halperin, LE Shapiro and MI Surks
Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York 10467.

The current consensus is that iodothyronines down-regulate type II T4 monodeiodinase (5'-DII) by an extranuclear acceleration of enzyme inactivation. We have investigated 5'-DII regulation in cultured GC cells, in which thyroid hormone responses are mediated by nuclear thyroid receptor (TR). GC cells actively converted T4 to T3, independent of propylthiouracil and with a Km of 1.4 nM, which are characteristics of 5'-DII. When GC cells were incubated with 10 nM T3, the Km was not affected. However, the maximum velocity was significantly down-regulated by 10 nM T3, from 0.15 to 0.018 pmol/mg protein.min. Dose-response studies showed that a 50% reduction in enzyme activity was achieved with either 0.25 nM T3 or 12 nM rT3. Time- course studies showed that a 50% reduction in enzyme activity occurred after 40 min of incubation with 100 nM rT3 and after 160 min of incubation with 10 nM T3. The down-regulation of 5'-DII by physiological concentrations of T3 has the characteristics of an effect that is mediated by nuclear TR. Our studies, therefore, suggest that down-regulation of 5'-DII by these iodothyronines in GC cells may occur by different mechanisms: enzyme inactivation for rT3, in agreement with the current consensus, and decreased enzyme production for T3, probably mediated by TR.

This article has been cited by other articles:

				S. Friedrichsen, S. Christ, H. Heuer, M. K. H. Schafer, A. Mansouri, K. Bauer, and T. J. Visser Regulation of Iodothyronine Deiodinases in the Pax8-/- Mouse Model of Congenital Hypothyroidism Endocrinology, March 1, 2003; 144(3): 777 - 784. [Abstract] [Full Text] [PDF]

				G. G. J. M. Kuiper, W. Klootwijk, and T. J. Visser Substitution of Cysteine for a Conserved Alanine Residue in the Catalytic Center of Type II Iodothyronine Deiodinase Alters Interaction with Reducing Cofactor Endocrinology, April 1, 2002; 143(4): 1190 - 1198. [Abstract] [Full Text] [PDF]

				A. C. Bianco, D. Salvatore, B. Gereben, M. J. Berry, and P. R. Larsen Biochemistry, Cellular and Molecular Biology, and Physiological Roles of the Iodothyronine Selenodeiodinases Endocr. Rev., February 1, 2002; 23(1): 38 - 89. [Abstract] [Full Text] [PDF]

				J. Steinsapir, A. C. Bianco, C. Buettner, J. Harney, and P. R. Larsen Substrate-Induced Down-Regulation of Human Type 2 Deiodinase (hD2) Is Mediated through Proteasomal Degradation and Requires Interaction with the Enzyme's Active Center Endocrinology, March 1, 2000; 141(3): 1127 - 1135. [Abstract] [Full Text] [PDF]

				S.-W. Kim, J. W. Harney, and P. R. Larsen Studies of the Hormonal Regulation of Type 2 5'-Iodothyronine Deiodinase Messenger Ribonucleic Acid in Pituitary Tumor Cells Using Semiquantitative Reverse Transcription-Polymerase Chain Reaction Endocrinology, December 1, 1998; 139(12): 4895 - 4905. [Abstract] [Full Text] [PDF]

				M. Safran, A. P. Farwell, and J. L. Leonard Catalytic Activity of Type II Iodothyronine 5'-Deiodinase Polypeptide Is Dependent upon a Cyclic AMP Activation Factor J. Biol. Chem., July 5, 1996; 271(27): 16363 - 16368. [Abstract] [Full Text] [PDF]